—
Market InsightsThe global X-linked hypophosphatemia market is likely to proliferate significantly from 2018 to 2023. The reports have been published by Market Research Future, and with the help of in-depth analysis and study, the analysts have come up with research study.
X-Linked hypophosphatemia (XLH) denotes as an inherited disorder which is characterized by the presence of low phosphate concentration in the blood. The therapy for X-linked hypophosphatemia essentially involves phosphate supplements, corrective surgery, dental treatment, and growth hormone therapy whereas; it leads to weakening of bones, which can give rise to prolonged physical disabilities and subsequent pain. Patients detected with x-linked hypophosphatemia usually suffer from having bent legs, bone pain, short stature, and are most prone to dental problems.
Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/6267
Global X-linked Hypophosphatemia Market: Drivers & Trends
The global x-linked hypophosphatemia market, therefore, continues to proliferate by several factors such as rising incidence of genetic diseases, rising expenditure on healthcare services as well as proactive initiatives that are being taken on research and development activities. These factors are highly expected to stimulate the x-linked hypophosphatemia market in the years to come, as per the research.
As per the research, the analysts have recorded that conferring to a press release by the US Food & Drug Administration (FDA) in April 2018, X-Linked Hypophosphatemia (XLH) has been denoted as a severe disease, that has affected approximately 3,000 children and 12,000 adults in the US. On top of it, the increasing number of researches on X-Linked Hypophosphatemia is also contributing largely to the market growth during the forecast period.
Similarly, many government bodies are wholly dedicated to improving the health of patients suffering from X-Linked Hypophosphatemia. However, the availability of limited treatment options coupled with lack of awareness about such disorder in some regions may cause as a hindrance to the global X-Linked Hypophosphatemia market growth in the years to come.
Key Players
MRFR has listed some of the key players in the global X-linked hypophosphatemia market. They are Ultragenyx Pharmaceutical Inc., Kyowa Hakko Kirin Co. Ltd., Validus Pharmaceuticals LLC, Nestlé S.A, Merck & Co., Inc., Pfizer, F. Hoffmann-La Roche Ltd., Koninklijke DSM N.V., ADM Alliance Nutrition, Inc., BASF, and Eli Lily and Company.
Industry News
March 26, 2019: Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the progress of innovative products for severe and ultra-rare genetic diseases, announced that Brazil’s National Health Surveillance Agency (ANVISA) had accepted Crysvita (burosumab) for the treatment of X-linked hypophosphatemia in adult and pediatric patients one year of age and older.
Check Discount at https://www.marketresearchfuture.com/check-discount/6267
Market Segmentation
According to the reports published by MRFR, the global X-linked hypophosphatemia market has been segmented as a symptom, diagnosis, treatment, and end-user.
On account of symptom, the market has been segmented as bone pain, muscle pain, short stature, abnormal tooth development, dental pain, craniosynostosis, and many others.
On account of diagnosis, the market has been segmented into blood test, urine test, genetic test, bone x-ray, and others.
On account of treatment, the market has been segmented into medication, corrective surgery, and dental procedures. Wherein, medication segment has been further segmented into oral phosphate supplements and vitamin D, growth hormones, and others.
On account of end-user, the market has been segmented into hospitals and clinics, diagnostic centers, and others.
Regional Outlook
On a geographical note, the global X-linked hypophosphatemia market has covered the major regions such as Americas, Europe, Asia Pacific, and the Middle East and Africa.
Among all, the global X-linked hypophosphatemia market in the Americas is expected to lead at the time of forecast period owing to the mounting presence of XLH coupling with the well-established healthcare sector in the region.
Similarly, the European market is also expected to be the second-largest one owing to vast government funding activities and support of the healthcare sector, increasing research and development, and rising prevalence of X-linked hypophosphatemia in the region. These factors are influencing the market to expand wisely and open new opportunities in the coming years.
Moreover, the market of X-linked hypophosphatemia in Asia-Pacific is anticipated to be the fastest-growing market in owing to technological developments and favorable government creativities for healthcare facilities in the forecast period.
Whereas, the X-linked hypophosphatemia market in the Middle East and Africa is likely to account for the having the smallest share of global X-linked hypophosphatemia market attributing to the swelling healthcare expenditure and low manufacturing costs of pharmaceuticals.
Browse Full Report at https://www.marketresearchfuture.com/reports/x-linked-hypophosphatemia-market-6267
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Info:
Name: Abhishek Sawant
Email: Send Email
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
Phone: 6468459312
Website: https://www.marketresearchfuture.com/reports/x-linked-hypophosphatemia-market-6267
Release ID: 523850
Google
RSS